HLB Pharmaceutical Co. Ltd (047920) — Cash Flow-to-Debt Ratio
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩1.86 Billion could theoretically repay 0% of its total liabilities (₩46.98 Billion) in one year. See HLB Pharmaceutical Co. Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HLB Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for HLB Pharmaceutical Co. Ltd across 11 annual periods. Also explore HLB Pharmaceutical Co. Ltd (047920) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for HLB Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see how much is HLB Pharmaceutical Co. Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.16x | ₩6.84 Billion | ₩41.53 Billion | ▲ +147.8% |
| 2023 | -0.34x | ₩-18.32 Billion | ₩53.20 Billion | ▼ -601.0% |
| 2022 | -0.05x | ₩-2.76 Billion | ₩56.25 Billion | ▼ -83.1% |
| 2021 | -0.03x | ₩-1.32 Billion | ₩49.25 Billion | ▼ -344.3% |
| 2020 | -0.01x | ₩-403.36 Million | ₩66.80 Billion | ▼ -113.0% |
| 2019 | 0.05x | ₩1.35 Billion | ₩29.04 Billion | ▲ +150.9% |
| 2018 | -0.09x | ₩-1.78 Billion | ₩19.42 Billion | ▼ -168.9% |
| 2017 | -0.03x | ₩-784.30 Million | ₩23.04 Billion | ▼ -256.8% |
| 2016 | -0.01x | ₩-213.11 Million | ₩22.34 Billion | ▲ +84.3% |
| 2015 | -0.06x | ₩-769.59 Million | ₩12.67 Billion | ▼ -165.4% |
| 2014 | 0.09x | ₩1.54 Billion | ₩16.62 Billion | — |